Key facts
- It has raised $77.5M; the latest was Early Stage VC ($77.5M) in Mar 2026.
- Notable investors include F-Prime Capital, Abingworth, Curie.Bio, DaVita Venture Group, SymBiosis (Bentonville) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for R1 Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for R1 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About R1 Therapeutics
Developer of therapeutics designed for the treatment of kidney disease. The company develops therapies focused on renal conditions using biotechnology-based research, clinical development processes, and targeted mechanisms of action that address kidney-related disorders, support disease management, and expand evidence-based therapeutic choices, enabling healthcare providers and patients in the nephrology market to access specialized treatment options and provide quality care to patients.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2025
- Website
- r1therapeutics.com/
- Ownership
- Privately Held (backing)
R1 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in R1 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on R1 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.